In Vivo EGFR Molecular Classification and Treatment Response

Harbin Medical University

Status: Completed

Conditions: Molecular Imaging

Treatments: Other: 18F-MPG

Study type: Interventional

Funder types: Other

Identifiers

NCT02717221

14400

Details and patient eligibility

About

The investigators developed 18F-MPG as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status. And use 18F-MPG to monitor EGFR-TKIs and chemotherapy treatment efficiency.

Full description

The goal of investigators were to evaluate the use of 18F-MPG as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-MPG in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers. And the investigators want to evaluated the use of 18F-MPG in adult NSCLC patients with EGFR mutational status received non-treatment, EGFR-TKIs and chemotherapy.

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Advanced NSCLC
• 18 years or older
• A life expectancy of at least 12 weeks
• Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
• Written informed consent

Exclusion criteria

• Claustrophobia
• Pregnancy
• Metal implants in the thorax

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

102 participants in 6 patient groups

18F-MPG:EGFR+

Experimental group

Description:

Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.

Treatment:

Other: 18F-MPG

18F-MPG:post-TKI EGFR+

Experimental group

Description:

Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.

Treatment:

Other: 18F-MPG

18F-MPG:post-chemo EGFR+

Experimental group

Description:

Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.

Treatment:

Other: 18F-MPG

18F-MPG:EGFR wild type

Experimental group

Description:

Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.

Treatment:

Other: 18F-MPG

18F-MPG:post-chemo EGFR wild type

Experimental group

Description:

Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.

Treatment:

Other: 18F-MPG

18F-MPG:unknown EGFR mutational status

Experimental group

Description:

Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group

Treatment:

Other: 18F-MPG